Entero Therapeutics (Nasdaq:ENTO) - Aktienkurs, Nachrichten und Analyse

ENTO Aktienübersicht

ENTO fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Die Erträge sind in den letzten 5 Jahren um 2.3% pro Jahr gestiegen.

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Hat keine nennenswerte Marktkapitalisierung ($5M)

Volatiler Aktienkurs in den letzten 3 Monaten

+ 1 mehr Risiko

Entero Therapeutics, Inc. Wettbewerber

Sonnet BioTherapeutics Holdings

NasdaqCM:SONN

US$5.1m

TC Biopharm (Holdings)

NasdaqCM:TCBP

US$5.2m

Rubius Therapeutics

OTCPK:RUBY

US$5.2m

Lipella Pharmaceuticals

NasdaqCM:LIPO

US$5.2m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Entero Therapeutics
Historical stock prices
Current Share Price	US$2.07
52 Week High	US$37.40
52 Week Low	US$1.98
Beta	1.35
1 Month Change	-30.54%
3 Month Change	-57.49%
1 Year Change	-94.12%
3 Year Change	-99.99%
5 Year Change	-100.00%
Change since IPO	-100.00%

Aktuelle Nachrichten und Updates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

AzurRx BioPharma, First Wave Bio in niclosamide licensing pact for gastrointestinal infections

Jan 04

AzurRx up 9% on advancement of mid-stage study of MS1819 in CF patients

Nov 30

Is AzurRx BioPharma (NASDAQ:AZRX) In A Good Position To Invest In Growth?

Nov 19

Aktionärsrenditen

	ENTO	US Biotechs	US Markt
7D	-15.3%	0.1%	1.2%
1Y	-94.1%	7.1%	20.8%

Rendite im Vergleich zur Industrie: ENTO unter dem Niveau der Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4% erzielte.

Rendite vs. Markt: ENTO hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is ENTO's price volatile compared to industry and market?
ENTO volatility
ENTO Average Weekly Movement	10.3%
Biotechs Industry Average Movement	10.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: ENTODer Aktienkurs des Unternehmens war in den letzten 3 Monaten unbeständig.

Volatilität im Zeitverlauf: ENTODie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 20% auf 15% gesunken, liegt aber immer noch über 75 % der Aktien von US.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2014	9	James Sapirstein	www.enterothera.com

Entero Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen im klinischen Stadium, das sich mit der Entwicklung von zielgerichteten und oral verabreichten Therapien zur Behandlung von Patienten mit Magen-Darm-Erkrankungen befasst. Zu den Pipeline-Kandidaten des Unternehmens gehören Latiglutenase, ein zielgerichtetes orales Biotherapeutikum zur Behandlung von Zöliakie, das Gluten in nicht-immunogene Peptide aufspaltet und sich derzeit in Phase-2-Studien befindet, sowie Capeserod, ein selektiver partieller 5-HT4-Rezeptor-Agonist, der sich in Phase-1-Studien zur Behandlung von Gastroparese befindet. Das Unternehmen ist auch an der Entwicklung von Adrulipase beteiligt, einem rekombinanten Lipase-Enzym, das die Verdauung von Fetten und anderen Nährstoffen ermöglichen soll und derzeit in Phase-2-Studien zur Behandlung der exokrinen Pankreasinsuffizienz bei Patienten mit zystischer Fibrose und chronischer Pankreatitis untersucht wird; und Niclosamid, ein oral verabreichter niedermolekularer Wirkstoff mit entzündungshemmender Wirkung, der derzeit in Phase-2-Studien zur Behandlung der ulzerativen Proktitis und der ulzerativen Proktosigmoiditis sowie der mit Immun-Checkpoint-Inhibitoren assoziierten Kolitis und Diarrhöe bei Patienten mit metastasierendem Krebs untersucht wird.

Entero Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Entero Therapeutics im Vergleich zum Marktanteil des Unternehmens?
ENTO grundlegende Statistiken
Marktanteil	US$5.12m
Gewinn(TTM)	-US$6.44m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-0.8x

Kurs-Gewinn-Verhältnis

Ist ENTO zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ENTO Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$6.44m
Umsatz	-US$6.44m

Zuletzt gemeldete Gewinne

Mar 31, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-2.60
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	8.7%

Wie hat sich ENTO auf lange Sicht entwickelt?

Historische Performance und Vergleiche

ENTO Aktienübersicht

Belohnungen

Risikoanalyse

Entero Therapeutics, Inc. Wettbewerber

NasdaqCM:SONN

US$5.1m

NasdaqCM:TCBP

US$5.2m

OTCPK:RUBY

US$5.2m

NasdaqCM:LIPO

US$5.2m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

Recent updates

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

No longer forecast to breakeven

AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma Inc Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Azurrx Biopharma, Inc. Adds New Clinical Trial Sites in Ukraine for Phase 2 Reservoir Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx BioPharma Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

AzurRx BioPharma, Inc. Doses First Patient in Phase 2 Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

Erträge & Einnahmen